Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
The live audio webcast will be available online, with telephone dial-ins for U.S./Canada, U.K., and international participants and a replay accessible until April 15, 2026 (Conference ID 13759627).
Senior management and scientific officers will present and take questions about 2025 events, subsequent developments, and upcoming milestones.
Volition (NYSE AMERICAN: VNRX) reported blinded validation results from 81 subjects showing strong detection performance using its Capture-Seq™ liquid biopsy for colorectal and lung cancer.
The cohort achieved ~95% detection for stage I and II cancers (I: 94% [17/18]; II: 96% [26/27]), overall sensitivity 93% (55/59) and specificity 95% (21/22). The company cites a combined $36 billion TAM ($23B MCED; $13B MRD) and says it is in active discussions with potential licensing partners to commercialize the technology.
Volition (NYSE AMERICAN: VNRX) reports a claimed world‑first method, Capture‑Seq™, producing >99% pure circulating tumor DNA (ctDNA) from plasma. The company submitted an updated manuscript and reports blinded cohort detection of 49/49 and 13/14 cancers. Volition cites a combined TAM of approximately $36 billion.
The company says it is in active discussions with diagnostic partners and expects the updated preprint on Research Square shortly.
Volition (NYSE AMERICAN: VNRX) completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation in central laboratories.
The supply agreement allows Fujifilm Vet Systems to sell and perform the automated test across its Japanese central reference lab network; over 1,700 veterinary hospitals are registered and Japan has about 7 million pet dogs, indicating a sizeable addressable market.
Volition (NYSE AMERICAN: VNRX) reported commercial and clinical progress across multiple pillars, including a peer‑review submission for the new Capture‑Seq cancer method (TAM $23B), imminent lung cancer reimbursement in France (routine use expected Q4 2026), inclusion in a $7.3M sepsis program, CE‑marked Nu.Q® NETs availability, and a feline lymphoma test achieving 100% specificity with a $5M milestone expected.
Volition (NYSE AMERICAN: VNRX) appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for Nu.Q® Discover assays in Japan on Feb 10, 2026.
The company serves close to 100 clients, reported substantial 2025 revenue growth for Nu.Q® Discover, cited a ~$1 billion Total Accessible Market, and listed several 2025 commercial and clinical milestones.
VolitionRx (NYSE AMERICAN: VNRX) received a NYSE American notice dated February 6, 2026, that it is not in compliance with stockholders' equity listing standards in Sections 1003(a)(i)-(iii).
The company must file a compliance Plan by March 8, 2026 to regain compliance by August 6, 2027, or face potential delisting proceedings; shares will trade with a ".BC" designation meanwhile.
Volition (NYSE: VNRX) sponsored a symposium at the European Hidradenitis Suppurativa Foundation conference in Malta on Feb 5, 2026, presenting clinical data for the Nu.Q® NETs plasma assay in Hidradenitis Suppurativa (HS).
The company highlighted a recently released cohort study suggesting Nu.Q® NETs can classify HS severity and may guide treatment selection; a related poster was presented Feb 4. The assay is CE‑Marked and commercially available across 27 EU member states, three EEA countries, and the U.K., and Volition cited a $3.8 billion total addressable market.
Volition (NYSE AMERICAN: VNRX) is preparing a reimbursement submission for its Nu.Q® Cancer assays to French government agencies, supported by Hospices Civils de Lyon (HCL). The dossier will run alongside clinical certification at HCL under the RIHN framework, with admissibility review followed by a reimbursement decision expected within five months.
The company cites ~50,000 new lung cancer diagnoses and ~65,000 five-year prevalence in France and anticipates routine clinical use in France by Q4 2026 while pursuing international partnerships and licensing opportunities.
Volition (NYSE: VNRX) announced a clinical study showing use of its Nu.Q® NETs assay to manage Hidradenitis Suppurativa (HS), a chronic immune-mediated disease affecting ~1% of the global population. The release notes the Nu.Q® NETs assay is CE‑Marked and commercially available across 27 EU member states, 3 EEA countries (Iceland, Liechtenstein, Norway) and the U.K.
The company cites a $3.8 billion Total Addressable Market (Data on File: Volition TAM Model) and says the test may help classify HS severity, guide treatment decisions and act as a surrogate marker for response, specifically noting circulating H3.1‑nucleosomes as a candidate blood marker. The paper is noted as available on medRXIV and includes prior related publications.